Affar, El Bachir
Carbone, Michele
Funding for this research was provided by:
U.S. Department of Defense (CA150220)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (RO1 CA198138)
Canadian HIV Trials Network, Canadian Institutes of Health Research (399244)
Article History
Received: 29 October 2018
Accepted: 2 November 2018
First Online: 19 November 2018
Conflict of interest
: None. For full disclosure Dr. Carbone declares that he has pending patent applications on BAP1, a patent using anti-HMGB1 monoclonal antibody or other HMGB1 antibodies as a novel mesothelioma therapeutic strategy, Patent No.: 9,561,274 issued, and a patent HMGB1 as a biomarker for asbestos exposure and mesothelioma early detection Application No.: 14/123,722 Patent No.: 9,244,074. Dr. Carbone is a board certified Pathologist and provides consultation for mesothelioma expertise and diagnosis, including paid medical-legal consulting. E.B.A. has nothing to disclose.